IBYME   02675
INSTITUTO DE BIOLOGIA Y MEDICINA EXPERIMENTAL
Unidad Ejecutora - UE
congresos y reuniones científicas
Título:
Antiprogestins administration to progesterone receptor isoform A (PRA)-overexpressing mammary carcinomas is associated with increased intratumor concentrations of doxorubicin and paclitaxel
Autor/es:
GONZALO SEQUEIRA, MARÍA MAY, PAOLA ROJAS, CAROLINE LAMB, ALFREDO MOLINOLO, CLAUDIA LANARI.
Reunión:
Congreso; Gordon Conferences; 2013
Resumen:
Chemotherapy is the standard treatment for metastatic breast cancer today. To overcome undesired side effects and improve drug efficacy in tumor cells, different nanoparticle formulations were developed. Paclitaxel was bound with human albumin (Nab-paclitaxel; Abraxane), and pegylated liposomes have been developed for doxorubicin delivery (PEG-LD; Doxopeg). We have evaluated the effect of these therapeutic agents together with antiprogestins in experimental murine mammary carcinomas (MMC) expressing different ratios of progesterone receptor (PR) isoforms and showed an increased therapeutic effect of combined treatments vs. single treatments only in tumors over expressing PR isoform A (PR-A). We showed that in these tumors antiprogestins such as Mifepristone (MFP) or Onapristone, induced tissue remodeling (1-3), increasing the stroma/parenchyma ratio and the number of vessels, increasing doxorubicin or Abraxane concentration within the tumors. (Sequeira et al., CTRC-AACR San Antonio Breast Cancer Symposium, December 4-8 2012